Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;17(2):528-530.
doi: 10.21037/jtd-24-1789. Epub 2025 Feb 27.

Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer

Naoki Furuya  1 , Takahiro Homma  2 , Hisashi Saji  2
Affiliations
Editorial

Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer

Naoki Furuya et al. J Thorac Dis. .
No abstract available

Keywords: Anti-LAG3 antibody; neoadjuvant immunotherapy; resectable non-small cell lung cancer (resectable NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1789/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Schuler M, Cuppens K, Plönes T, et al. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nat Med 2024;30:1602-11. 10.1038/s41591-024-02965-0 - DOI - PMC - PubMed
    1. Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 2022;386:1973-85. 10.1056/NEJMoa2202170 - DOI - PMC - PubMed
    1. Cascone T, Awad MM, Spicer JD, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med 2024;390:1756-69. 10.1056/NEJMoa2311926 - DOI - PubMed
    1. Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med 2023;389:491-503. 10.1056/NEJMoa2302983 - DOI - PMC - PubMed
    1. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med 2023;389:1672-84. 10.1056/NEJMoa2304875 - DOI - PubMed

LinkOut - more resources